In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp.

International Journal of Antimicrobial Agents

Volumn 28, Issue 5, 2006, Pages 454-456

  Tong, WeiHang ^a   Wang, Rui ^a   Chai, Dong ^a   Li, ZhaoXia ^a   Pei, Fei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Acinetobacter spp.; Carbapenem resistance; Cefepime; Sulbactam; Synergy

Indexed keywords

CARBAPENEM; CEFEPIME; SULBACTAM;

ACINETOBACTER BAUMANNII; ACINETOBACTER JUNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ESCHERICHIA COLI; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; SULBACTAM;

EID: 33750285153     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.08.008     Document Type: Article

References (14)

1. Bergogne-Berezin E., and Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9 (1996) 148-165
2. Gales A.C., Jones R.N., Forward K.R., Linares J., Sader H.S., and Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 32 Suppl. 2 (2001) S104-S113
3. Go E.S., Urban C., Burns J., et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344 (1994) 1329-1332
4. Corbella X., Montero A., Pujol M., et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 38 (2000) 4086-4095
5. Manikal V.M., Landman D., Saurina G., Oydna E., Lal H., and Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 31 (2000) 101-106
6. Mimoz O., Leotard S., Jacolot A., et al. Efficacies of imipenem, meropenem, cefepime and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing β-lactamase-producing strain of Enterobacter cloacae. Antimicrob Agents Chemother 44 (2000) 885-890
7. Higgins P.G., Wisplinghoff H., Stefanik D., and Seifert H. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 48 (2004) 1586-1592
8. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Supplemental tables M100-S15. Wayne, PA: NCCLS; 2005.
9. Moody J. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: Isenberg H.D. (Ed). Clinical microbiology procedures handbook. 2nd ed. (2004), ASM Press, Washington, DC 1-28
10. Wang H., Liu Y.M., Chen M.J., Sun H.L., Xie X.L., and Xu Y.C. Mechanism of carbapenems resistance in Acinetobacter baumannii. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 25 (2003) 567-572 [in Chinese]
11. JiangXiao Fei, Yue Jun, Hong Xiuhua, et al. A clinic strain of Acinetobacter baumannii which produces OXA-23 carbapenems and per-1 type ESBLs. Shanghai J Med Lab Sci 2002;17:263-7 [in Chinese].
12. Kiffer C.R.V., Sampaio J.L.M., Sinto S., et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 52 (2005) 317-322
13. Sader H.S., and Jones R.N. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int J Antimicrob Agents 25 (2005) 380-384
14. Appleman M.D., Belzberg H., Citron D.M., et al. In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother 44 (2000) 1035-1040